SPARTA: c-MET Inhibitor APL-101 for Patients with c-MET Altered Solid Tumors

Condition: Solid Tumors

Sponsor: Apollomics Inc.

Full Title
APL-101-01: A Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Study Treatment
Oral small molecule c-MET inhibitor APL-101

Eligibility/Info
Cohort A1: NSCLC, MET exon 14 skip, line 1, MET inhibitor naïve
Cohort A2: NSCLC, MET exon 14 skip, line 2-3, MET inhibitor naïve
Cohort B: CLOSED
Cohort C: Advanced solid tumors, c-MET amplification, no available standard of care, ≤3 prior lines, MET inhibitor naïve
Cohort C1: NSCLC, c-MET amplification, EGFR wild type, MET inhibitor naïve
Cohort D: Advanced solid tumors, c-MET fusion, no available standard of care, ≤3 prior lines, MET inhibitor naïve

Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.